1.	An Extension Protocol for Subjects Who Were Previously Enrolled in Other ARQ 197 Protocols Phase: Phase II, Phase I Type: Treatment Status: Active Age: Not specified Sponsor: Pharmaceutical / Industry Protocol IDs: ARQ 197-299, NCT01178411
2.	Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 anad over Sponsor: Other Protocol IDs: SCRI GI 157, NCT01611857
3.	Erlotinib Plus ARQ 197 Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ARQ 197-218, NCT01395758
4.	Phase II Study of c-Met Inhibitor ARQ 197 (Tivantinib) in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: MDA-2011-0197, 2011-0197, 8984, NCT01447914
5.	Phase II Randomized Study of Tivantinib in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: OSU-11132, OSU11132, 8986, NCT01519414
6.	ARQ197 in Metastatic Triple-Negative Breast Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18and over Sponsor: Other Protocol IDs: 12-017, NCT01542996
7.	Phase II Study of Tivantinib in Patients With Triple-Negative Recurrent or Metastatic Breast Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: DFCI-12-017, 12-017, 8985, NCT01575522
8.	ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer Phase: Phase II Type: Treatment Status: Active Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ARQ 197-007, 23-4882, NCT01580735
9.	Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot be Removed by Surgery Phase: Phase II Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment Status: Active Age: Not specified Sponsor: NCI Protocol IDs: NCI-2012-01641, U10CA032102, S1107, NCT01688973
10.	Pazopanib and ARQ 197 for Advanced Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 120009, 12-C-0009, NCT01468922
11.	Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects Phase: Phase I Type: Biomarker/Laboratory analysis Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ARQ197-A-U158, NCT01517399
12.	Tivantinib and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-00949, CO 11914, U01CA062491, NCT01625156
13.	Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors or Recurrent Small Cell Lung Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-01220, U01CA062505, PHI-68, NCT01654965
14.	Study of ARQ 197 in Hepatocellular Carcinoma (HCC) Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ARQ 197-008, NCT01656265